RE: One liner17 Nov 2019 11:08
Yes, it looks like 002 will be the big short term winner for NFX in a deal with Kissei.
Though from the company response to the Times I also expect a new and wider deal with NSB/Yatai (to include the mysterious additional applications from the last 001 pre-clinical milestone). I think this will be more valuable than than just the CINV applications and will explain why the outstanding milestone payments are being incorporated into a new deal.
However, beyond 001 and 002, the potential of the Ebers collaboration is just huge. Ebers obviously think so (... up to £51 million of upfront, R&D and milestone payments, plus long-term royalties of 20% of net sales to NFX). Dan has emphasised the importance of getting as much IP acreage as possible in this space and someone, somewhere is going to transform pain management worldwide based on cbd research. It would be nice if it was NFX. :)